** Shares of Aldeyra Therapeutics rise 1.9% to $5.40 premarket
** Co says it has resubmitted its application for approval to the U.S. FDA for its dry eye disease drug
** Last year, the FDA declined to approve the drug reproxalap
** Up to last close, stock up 51% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments